Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.4K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Abnormal Proliferation02:23

Abnormal Proliferation

4.9K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

955
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
955
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Follistatin Mitigates Atherosclerosis Through Activation of Arginine Metabolism and Adipose Browning.

Cells·2026
Same author

SUCNR1 coordinates metabolic flux, mitochondrial function, and nutrient-dependent adaptation in hepatocytes.

Science advances·2026
Same author

Corrigendum to: ApoB100 remodeling and stiffened cholesteryl ester core raise LDL aggregation in familial hypercholesterolemia patients [Journal of Lipid Research 66/1 (2025) 100703].

Journal of lipid research·2026
Same author

Special issue: Lipid metabolic alterations in cancer: Pathogenic mechanisms, therapies and common pathophysiology with cardiovascular disease.

Seminars in cancer biology·2026
Same author

Polymeric immunoglobulin receptor deficiency attenuates experimental atherosclerosis.

Frontiers in immunology·2026
Same author

Altered small dense LDL profiles in long-standing controlled type 1 diabetes.

Frontiers in endocrinology·2026

Related Experiment Video

Updated: Nov 30, 2025

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.1K

Apolipoprotein mimetics in cancer.

Samuel C Delk1, Arnab Chattopadhyay2, Joan Carles Escola-Gil3

  • 1Molecular Toxicology Interdepartmental Degree Program, Fielding School of Public Health, University of California, Los Angeles, CA, 90095, USA; Department of Medicine, Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.

Seminars in Cancer Biology
|November 14, 2020
PubMed
Summary

Apolipoprotein mimetic peptides show promise as cancer therapeutics due to low toxicity. These peptides, particularly apolipoprotein A-I (apoA-I) mimetics, target various cancers by modulating lipid metabolism and inflammation.

Keywords:
ApoA-ICancerHDLMimetic peptidesNanoparticles

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.9K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.0K

Related Experiment Videos

Last Updated: Nov 30, 2025

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.1K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.9K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.0K

Area of Science:

  • Biochemistry
  • Oncology
  • Drug Discovery

Background:

  • Peptides offer advantages over traditional therapeutics, including low toxicity and immunogenicity.
  • High-density lipoprotein (HDL) constituents like apolipoprotein A-I (apoA-I) possess anti-tumorigenic properties.
  • Apolipoprotein mimetic peptides are designed to replicate the function of native apolipoproteins.

Purpose of the Study:

  • To review the benefits and mechanisms of apolipoprotein mimetic peptides in cancer.
  • To explore their potential in treating various malignancies.
  • To discuss their application in drug delivery systems.

Main Methods:

  • Molecular mimicry to develop peptides mimicking apoA-I's amphipathic α-helices.
  • Preclinical models to assess efficacy against ovarian, colon, breast, and lung cancers.
  • Investigation of reconstituted HDL as targeted nanoparticles for drug delivery.

Main Results:

  • Oral apoA-I mimetic peptides modulate HDL, cholesterol efflux, and inflammation.
  • ApoA-I and apoJ mimetic peptides inhibit cancer progression in preclinical studies.
  • Reconstituted HDL acts as a nanoparticle for targeted tumor delivery, crossing the blood-brain barrier.

Conclusions:

  • Apolipoprotein mimetic peptides and HDL-based nanoparticles are promising, safe therapeutic and drug delivery agents for cancer.
  • The small intestine is a key site of action for apoA-I mimetic peptides, involving immune cell modulation.
  • Further research supports their utility in treating diverse cancers, including metastatic lung cancer.